enGene Therapeutics Inc. reported its financial results for the quarter and six months ended April 30, 2026. The company experienced net losses of $30.2 million and $59.9 million for the three and six-month periods, respectively. Operating expenses increased due to higher research and development and general and administrative costs. A significant strategic restructuring was announced, including a workforce reduction of approximately 50% to streamline operations and preserve cash. The company expects to incur restructuring costs between $5.7 million and $6.4 million, plus $4.7 million to $5.0 million in non-cash stock-based compensation. enGene Therapeutics anticipates its current cash, cash equivalents, and marketable securities will be sufficient for at least the next 12 months. The company is advancing its lead drug candidate, detalimogene, with plans to engage with the FDA and initiate a Biologics License Application (BLA) submission in the second half of 2026. Updated interim results from the pivotal LEGEND trial showed a 54.0% any-time complete response rate among evaluable patients as of April 21, 2026.